Literature DB >> 3234463

Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation.

J Drewe1, N Mazer, E Abisch, K Krummen, M Keck.   

Abstract

The influence of food on release of drug from a modified release capsule of bromocriptine 5 mg (Parlodel SRO) and a conventional formulation of bromocriptine 5 mg has been studied in 8 healthy male volunteers. Both formulations produced objective and subjective effects, such as orthostatic reactions, nausea, dizziness, vomiting and nasal congestion. The modified release capsule caused fewer side-effects than the normal capsule. Both formulations had less cardiovascular effect in the fed than in the fasting state. There was no significant difference between the normal and the modified release capsules taken fasting or after a meal in terms of the AUC extrapolated to infinity. The relative bioavailability of the 5 mg modified release capsule was 84.6% of the normal capsule under fasting conditions and 107.5% after food. In contrast to the virtually unchanged extent of absorption, the rate of absorption was markedly affected by food, especially from the conventional capsule. The mean time of 50% absorption increased from 1.06 h (fasting) to 3.2 h (fed), whereas for the modified release capsule food mainly resulted in an increased lag time of absorption. The almost instantaneous dissolution of bromocriptine from the normal capsule in vitro (both in HCl and fasting human gastric juice) and the delay of absorption after a meal in vivo suggest that the rate limiting step in absorption of the normal capsules is delivery of released drug from the stomach to the small intestine, which is delayed by food. Both the modified release 5-mg capsule and the normal 5-mg capsule showed extended suppression of prolactin over 36 h, in all subjects, both fasted and after a meal.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234463     DOI: 10.1007/bf00558250

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

Review 2.  Influence of food on the bioavailability of drugs.

Authors:  A Melander
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

3.  Long-term ambulatory gastric pH monitoring: validation of a new method and effect of H2-antagonists.

Authors:  C J Fimmel; A Etienne; T Cilluffo; C von Ritter; T Gasser; J P Rey; P Caradonna-Moscatelli; F Sabbatini; F Pace; H W Bühler
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

4.  Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition.

Authors:  P Mojaverian; R K Ferguson; P H Vlasses; M L Rocci; A Oren; J A Fix; L J Caldwell; C Gardner
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

5.  Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal.

Authors:  N J Woodhouse; N Niles; D McDonald; S McCorkell
Journal:  Horm Res       Date:  1985

6.  Gastric processing and emptying of fat.

Authors:  J H Meyer; E A Mayer; D Jehn; Y Gu; A S Fink; M Fried
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

  6 in total
  9 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.

Authors:  C Brefel; C Thalamas; S Rayet; A Lopez-Gil; K Fitzpatrick; S Bullman; D R Citerone; A C Taylor; J L Montastruc; O Rascol
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 4.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

5.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

Authors:  J B Schulz; T Klockgether; D Petersen; M Jauch; W Müller-Schauenburg; S Spieker; K Voigt; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 6.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

7.  Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration.

Authors:  Roshan Cools; Michael J Frank; Sasha E Gibbs; Asako Miyakawa; William Jagust; Mark D'Esposito
Journal:  J Neurosci       Date:  2009-02-04       Impact factor: 6.167

9.  Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.

Authors:  Nobuaki Shiraki; Keiko Okamura; Jin Tokunaga; Takafumi Ohmura; Kazuto Yasuda; Takeo Kawaguchi; Akinobu Hamada; Masahiro Nakano
Journal:  Jpn J Cancer Res       Date:  2002-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.